{"id":"https://openalex.org/W95077935","doi":"https://doi.org/10.1097/00002030-199904160-00008","title":"HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment","display_name":"HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment","alternate_titles":[],"publication_year":1999,"publication_date":"1999-04-01","ids":{"openalex":"https://openalex.org/W95077935","doi":"https://doi.org/10.1097/00002030-199904160-00008","mag":"95077935","pmid":"https://pubmed.ncbi.nlm.nih.gov/10397562"},"language":"en","primary_location":{"id":"doi:10.1097/00002030-199904160-00008","doi":"https://doi.org/10.1097/00002030-199904160-00008","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002030-199904160-00008","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W95077935"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015778932","display_name":"Avidan Uriel Neumann","orcid":"https://orcid.org/0000-0002-2149-5917","observed_orcids":["https://orcid.org/0000-0002-2149-5917"]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]},{"id":"https://openalex.org/I13955877","display_name":"Bar-Ilan University","ror":"https://ror.org/03kgsv495","country_code":"IL","type":"education","lineage":["https://openalex.org/I13955877"]}],"countries":["FR","IL"],"is_corresponding":true,"raw_author_name":"Avidan U. Neumann","raw_affiliation_strings":["Laboratoire d'Immunologie Cellulaire, URA CNRS 625, Paris, France","Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel. The Comet study group includes the authors and Hocine Ait-Mohand, Mayeule Legrand, Alain Mallet, Mich\u00e8le Pauchard and Isabelle Porcher"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Laboratoire d'Immunologie Cellulaire, URA CNRS 625, Paris, France","institution_ids":["https://openalex.org/I1294671590"]},{"raw_affiliation_string":"Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel. The Comet study group includes the authors and Hocine Ait-Mohand, Mayeule Legrand, Alain Mallet, Mich\u00e8le Pauchard and Isabelle Porcher","institution_ids":["https://openalex.org/I13955877"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5107599945","display_name":"Roland Tubiana","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Roland Tubiana","raw_affiliation_strings":["Service des Maladies Infectieuses et Tropicales, and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service des Maladies Infectieuses et Tropicales, and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026234029","display_name":"Vincent C\u00e1lvez","orcid":"https://orcid.org/0009-0002-6855-3472","observed_orcids":["https://orcid.org/0009-0002-6855-3472"]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Vincent Calvez","raw_affiliation_strings":["Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","institution_ids":["https://openalex.org/I1294671590"]},{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France","institution_ids":["https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103001352","display_name":"C Robert","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Catherine Robert","raw_affiliation_strings":["Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","institution_ids":["https://openalex.org/I1294671590"]},{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France","institution_ids":["https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044459845","display_name":"Taisheng Li","orcid":"https://orcid.org/0000-0002-7050-5675","observed_orcids":["https://orcid.org/0000-0002-7050-5675","https://orcid.org/0000-0002-4575-2404"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Tai-Sheng Li","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084209829","display_name":"Henri Agut","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1294671590","display_name":"Centre National de la Recherche Scientifique","ror":"https://ror.org/02feahw73","country_code":"FR","type":"government","lineage":["https://openalex.org/I1294671590"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Henri Agut","raw_affiliation_strings":["Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France; and the","institution_ids":["https://openalex.org/I1294671590"]},{"raw_affiliation_string":"Service de Virologie, CNRS EP57, CRIV Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France","institution_ids":["https://openalex.org/I1294671590"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042701070","display_name":"Brigitte Autran","orcid":"https://orcid.org/0000-0002-3993-9336","observed_orcids":["https://orcid.org/0000-0002-3993-9336"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Brigitte Autran","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5017386021","display_name":"Christine Katlama","orcid":"https://orcid.org/0000-0002-5093-4800","observed_orcids":["https://orcid.org/0000-0002-5093-4800"]},"institutions":[{"id":"https://openalex.org/I4210121705","display_name":"Piti\u00e9-Salp\u00eatri\u00e8re Hospital","ror":"https://ror.org/02mh9a093","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210121705"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Christine Katlama","raw_affiliation_strings":["Date of receipt: 26 November 1998; revised 25 January 1999; accepted 1 February 1999","Professor Christine Katlama, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, 83 Boulevard de l\u201aH\u00f4pital, Paris 75013, France. E-mail: [email\u00a0protected]","Service des Maladies Infectieuses et Tropicales, and","Sponsorship: This work was supported by grants from the Agence Nationale de la Recherche contre le Sida (ANRS, Paris), and funded by the Fondation pour la Recherche Medicale, Paris (Sidaction)","The first two authors have equally contributed to this work"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Date of receipt: 26 November 1998; revised 25 January 1999; accepted 1 February 1999","institution_ids":[]},{"raw_affiliation_string":"Professor Christine Katlama, Service des Maladies Infectieuses et Tropicales, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, 83 Boulevard de l\u201aH\u00f4pital, Paris 75013, France. E-mail: [email\u00a0protected]","institution_ids":["https://openalex.org/I4210121705"]},{"raw_affiliation_string":"Service des Maladies Infectieuses et Tropicales, and","institution_ids":[]},{"raw_affiliation_string":"Sponsorship: This work was supported by grants from the Agence Nationale de la Recherche contre le Sida (ANRS, Paris), and funded by the Fondation pour la Recherche Medicale, Paris (Sidaction)","institution_ids":[]},{"raw_affiliation_string":"The first two authors have equally contributed to this work","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5015778932","https://openalex.org/A5042701070","https://openalex.org/A5044459845"],"corresponding_institution_ids":["https://openalex.org/I1294671590","https://openalex.org/I13955877"],"apc_list":null,"apc_paid":null,"fwci":8.4107,"has_fulltext":false,"cited_by_count":191,"citation_normalized_percentile":{"value":0.98749256,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"13","issue":"6","first_page":"677","last_page":"683"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.7778000235557556,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.7778000235557556,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.18950000405311584,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.023800000548362732,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antiretroviral-therapy-interruption","display_name":"antiretroviral therapy interruption","score":0.9169999957084656},{"id":"https://openalex.org/keywords/indinavir","display_name":"indinavir","score":0.7820000052452087},{"id":"https://openalex.org/keywords/zidovudine","display_name":"zidovudine","score":0.984000027179718},{"id":"https://openalex.org/keywords/lamivudine","display_name":"lamivudine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/antiretroviral-drug-resistance","display_name":"antiretroviral resistance","score":0.8379999995231628},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.6129999756813049},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.7979999780654907},{"id":"https://openalex.org/keywords/antiretroviral-naive-patients","display_name":"antiretroviral-naive patients","score":0.8690000176429749}],"concepts":[{"id":"https://openalex.org/C2777210460","wikidata":"https://www.wikidata.org/wiki/Q425490","display_name":"Indinavir","level":5,"score":0.8499731421470642},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.8415866494178772},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.7543721795082092},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.7478087544441223},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.6987591981887817},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6803076267242432},{"id":"https://openalex.org/C140206745","wikidata":"https://www.wikidata.org/wiki/Q5308895","display_name":"Drug holiday","level":3,"score":0.5402339100837708},{"id":"https://openalex.org/C2781143361","wikidata":"https://www.wikidata.org/wiki/Q55761529","display_name":"Protease inhibitor (pharmacology)","level":5,"score":0.4944009780883789},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.48663029074668884},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.46501046419143677},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.4320252537727356},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.42565348744392395},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3569175899028778},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3473803699016571},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3369755148887634},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.30525344610214233},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.2984921932220459},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.2330242395401001},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":true},{"descriptor_ui":"D017320","descriptor_name":"HIV Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D018791","descriptor_name":"CD4 Lymphocyte Count","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019469","descriptor_name":"Indinavir","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00002030-199904160-00008","doi":"https://doi.org/10.1097/00002030-199904160-00008","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00002030-199904160-00008","pdf_url":null,"source":{"id":"https://openalex.org/S20605092","display_name":"AIDS","issn_l":"0269-9370","issn":["0269-9370","1473-5571"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS","raw_type":"journal-article"},{"id":"pmid:10397562","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10397562","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"AIDS (London, England)","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1531777139","https://openalex.org/W1982448824","https://openalex.org/W1996168633","https://openalex.org/W2005281007","https://openalex.org/W2043519223","https://openalex.org/W2051269276","https://openalex.org/W2056169141","https://openalex.org/W2060735144","https://openalex.org/W2115991559","https://openalex.org/W2127765564","https://openalex.org/W2157390600","https://openalex.org/W2163345314","https://openalex.org/W2165770193","https://openalex.org/W2329393410","https://openalex.org/W2339219218"],"related_works":["https://openalex.org/W2168795464","https://openalex.org/W2321766273","https://openalex.org/W2783180623","https://openalex.org/W2333552643","https://openalex.org/W2055146856","https://openalex.org/W2077916906","https://openalex.org/W2035215938","https://openalex.org/W2026984650","https://openalex.org/W2160020204","https://openalex.org/W2623705220"],"abstract_inverted_index":{"BACKGROUND:":[0],"Potent":[1],"antiretroviral":[2],"therapy":[3,33,43,108,124,181,219,247,277],"(ART)":[4],"with":[5,72,109,118,142,231,266],"a":[6,127,138,143,232,249],"protease":[7,201],"inhibitor-based":[8],"regimen":[9,77,94],"is":[10,263,300],"commonly":[11],"used":[12],"to":[13,175,225,257,293],"treat":[14],"HIV-1-infected":[15,52],"patients.":[16],"Transient":[17],"treatment":[18,296],"interruptions":[19],"because":[20,288],"of":[21,42,59,66,107,111,120,129,147,156,160,164,183,206,238,244,259,269,308],"drug":[22,75],"intolerance":[23],"or":[24],"other":[25],"reasons":[26],"are":[27],"not":[28,45,264],"uncommon.":[29],"HIV-1":[30,98,196],"dynamics":[31],"during":[32,102,115,178,295],"interruption":[34,157,205,252],"and":[35,62,114,185,200,262],"its":[36],"consequences":[37],"for":[38,79,86,220],"the":[39,73,91,103,165,179,195,204,267,275],"subsequent":[40],"reinitiation":[41,163],"have":[44],"been":[46],"properly":[47],"studied.":[48],"METHODS:":[49],"Ten":[50],"antiretroviral-naive,":[51],"subjects":[53,217],"(mean":[54],"baseline":[55,294],"CD4":[56,234],"cell":[57,235],"count":[58,236],"414":[60],"cells/mm3":[61],"plasma":[63,100],"viral":[64,140,151,169,209,254,289,298],"load":[65,152,170,290],"4.8":[67],"log10":[68],"copies/ml)":[69],"were":[70,192,211],"treated":[71],"triple":[74],"ART":[76,93,167,246,285],"indinavir/zidovudine/lamivudine":[78],"28":[80,87,154],"days.":[81,122,149],"Therapy":[82],"was":[83,95,125,132,158,278],"then":[84],"interrupted":[85],"days,":[88,113,187],"after":[89,153,203,248],"which":[90],"same":[92,166],"re-started.":[96],"RESULTS:":[97],"in":[99,134,194,216,280,301],"declined":[101,171],"first":[104],"7":[105],"days":[106,116,131,155],"T1/2":[110,119],"1.5":[112],"7-28":[117],"8.9":[121],"Once":[123],"interrupted,":[126],"delay":[128],"4-7":[130],"observed":[133,177,193,279],"all":[135],"subjects,":[136],"preceding":[137],"rapid":[139],"rebound":[141],"mean":[144,233],"doubling":[145],"time":[146],"1.6":[148,184],"Mean":[150],"96%":[159],"baseline.":[161],"Upon":[162],"regimen,":[168],"at":[172],"rates":[173],"similar":[174,256],"those":[176],"initial":[180],"(T1/2":[182],"8.0":[186],"respectively).":[188],"No":[189,271],"resistance-conferring":[190],"mutations":[191],"reverse":[197],"transcriptase":[198],"(RT)":[199],"regions":[202],"therapy.":[207,286],"Plasma":[208],"loads":[210],"maintained":[212],"below":[213],"200":[214],"copies/ml":[215],"continuing":[218],"4":[221],"(n":[222,227],"=":[223,228],"9)":[224],"12":[226],"5)":[229],"months,":[230],"increase":[237],"145":[239],"cells/mm3.":[240],"CONCLUSIONS:":[241],"The":[242],"reintroduction":[243],"efficient":[245],"1":[250],"month":[251],"shows":[253],"kinetics":[255],"that":[258,306],"naive":[260],"patients,":[261],"associated":[265],"development":[268],"resistance.":[270],"deleterious":[272],"effect":[273,302],"on":[274],"reinitiated":[276],"patients":[281],"who":[282],"temporarily":[283],"discontinued":[284],"Nevertheless,":[287],"rebounds":[291],"back":[292],"interruption,":[297],"suppression":[299],"put":[303],"off":[304],"by":[305],"period":[307],"time.":[309]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W95077935","counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-17T12:49:18.490984","created_date":"2016-06-24T00:00:00"}
